Clinical trial
Anecortave Acetate Risk-Reduction Trial (AART)
NCT00333216 · Alcon Research, Industry · Terminated
Key facts
| NCT number | NCT00333216 |
|---|---|
| Title | Anecortave Acetate Risk-Reduction Trial (AART) |
| Official title | Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD) |
| Lead sponsor | Alcon Research, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | AMD |
| Intervention type | Drug, Other |
| Interventions | Anecortave Acetate Sterile Suspension, 30 mg/mL, 60 mg/ML, Anecortave Acetate Vehicle |
| Enrollment | 24 |
| Start date | May 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jun 2, 2006 |
| Last update posted | Nov 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: